- 6-12 months (every 2-3 weeks)
- 1-3 days per cycle
- 70%
China versus the U.S.
- China clinical rate
- $3,000 – $8,000
- $5,500
- United States
- $12,000 – $25,000
- $18,500
- You save
- ~70%
- $13,000 per procedure
Prices are approximate ranges. Actual cost depends on hospital, surgeon, materials, and case complexity.
What the procedure involves.
China has developed multiple PD-1 inhibitors including sintilimab (Innovent), tislelizumab (BeiGene), camrelizumab (Hengrui), and toripalimab (Junshi) at a fraction of US pricing. These domestically-developed drugs have been validated in major clinical trials and approved for lung, liver, gastric, and esophageal cancers. With 60-75% cost savings per cycle compared to pembrolizumab or nivolumab in the US, China offers world-class immunotherapy backed by extensive real-world treatment data.
Step by step.
Biomarker Testing
Comprehensive genomic profiling including PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) status to predict treatment response.
Treatment Plan Design
Oncology team designs personalized immunotherapy protocol, selecting optimal drug and combination strategy based on cancer type and biomarker results.
Infusion Sessions
Intravenous immunotherapy infusions administered every 2-3 weeks in outpatient oncology centers with monitoring for infusion reactions.
Response Assessment Imaging
Regular CT/MRI scans every 6-8 weeks to evaluate tumor response using iRECIST criteria, with treatment continuation or modification based on results.
- 60-75% cost savings with domestically developed PD-1 inhibitors
- Wide cancer coverage including lung, liver, gastric, and esophageal cancers
- Can be combined with chemotherapy for enhanced efficacy
- Extensive real-world data from large Chinese patient populations
- Immune-related adverse events affecting thyroid, liver, lungs, or skin
- Not all patients respond to immunotherapy (30-40% response rate varies by cancer)
- Requires regular monitoring with blood tests and imaging
- Potential for severe autoimmune reactions requiring treatment discontinuation
Ask the AI for hospitals that handle cancer immunotherapy (pd-1/pd-l1).
Prices shown are approximate ranges for reference only. Actual costs vary by hospital, complexity, and individual patient needs. Always consult with healthcare professionals for medical decisions.